Recombinant adeno-associated virus (rAAV) is a promising vector for retinal application as it transduces photoreceptors and retinal pigment epithelium cells efficiently and in a stable fashion. Because rAAV also transduces retinal ganglion cells, we reasoned that ocular application of rAAV might result in delivery of transgenic protein to the CNS. Here we describe high levels of green fluorescent protein (GFP) persisting at least 6 months in optic nerves and brains of mice and dogs after intravitreal delivery of rAAV-GFP. There was no clinical or histological evidence of inflammatory response although a mild humoral Th-2 response to viral capsid proteins was detected. These findings have important implications with respect to therapeutic applications of rAAV.
Introduction
Recombinant adeno-associated virus (rAAV) promises to be a useful vector for retinal application as it is replication-defective, has not been associated with any human disease and transduces photoreceptors and retinal pigment epithelium (RPE) cells efficiently and in a stable fashion. Because rAAV also transduces retinal ganglion cells (although at low levels) (Bennett, Duan, Engelhardt & Maguire, 1997) , we reasoned that ocular application of rAAV might result in delivery of transgenic protein to axons projecting from these cells-axons which travel through the optic nerve to various tracts in the brain. The ability to access the brain through a single intraocular injection would invite a number of scientific and clinical applications. Such applications could range from studies delineating fine anatomical pathways between the eye and the brain to non-invasive delivery of experimental/therapeutic molecules to internal brain structures. Here we describe high levels of the green fluorescent protein (GFP) in the optic tracts of the brain after intraocular delivery of rAAV containing the cDNA encoding GFP (AAV-GFP). Experiments were performed in cohorts (60 mice/120 eyes) of C57Bl/6 mice. In order to establish generality of the result, experiments were performed in a smaller number of eyes in a second species (two dogs/four eyes). The dog eye is anatomically more similar to the human eye than the mouse eye (it is larger, has a cone-enriched region analogous to the macula and has a holangiotic blood supply). In both mice and dogs, GFP was detected in the central nervous system (CNS) tissues known to be enervated by retinal ganglion cells (Glaser & Sadun, 1990) . GFP was stable, with high levels detectable at the longest timepoints (6 months). Neither the rAAV nor presence of GFP resulted in clinical or histological evidence of inflammatory response. Although animals developed antibodies to viral capsid proteins, they did not develop transgene-specific antibodies. The studies indicate that toxicity studies of rAAV-mediated retinal gene therapy should assess the possibility that intraocular delivery of AAV can result in delivery of the transgene product from the retina to the brain.
Methods

Virus preparation
AAV -GFP was prepared by packaging the recombinant DNA into AAV particles by complementation with a system expressing AAV rep and cap genes in Ad-lacZ-infected 293 cells (Bennett et al., 1997; Duan, Fisher, Burda & Engelhardt, 1997) . The transgene cassette consisted of the EGFP variant of the GFP cDNA (Clontech, Palo Alto, CA) under control of a cytomegalovirus (CMV) promoter. Titer of the purified virus was determined by infectious unit assay on 293 cells and by slot blot for virion DNA particles. Purified rAAV-GFP was tested for adenovirus contamination as described (Bennett et al., 1997) . No adenovirus was detected. The AAV-GFP was also tested for contamination with wild type AAV. This was performed by infecting 293 cells with rAAV -GFP in the presence of adenovirus and analyzing DNA harvested from the resulting lysate by Southern analysis using a Rep probe. Rep, reflecting the presence of wild-type AAV, was variably detected, never at levels greater than 0.1%.
Ad.CMVGFP, which contains the same promoter and transgene cassette as the rAAV -GFP, was purified to 5× 10 11 pfu ml − 1 from 293 cells as described. Aliquots of virus were tested for the presence of contaminating wildtype adenovirus by PCR amplification of the adenovirus E1a region (deleted from the recombinants) as described (Bennett, Zeng, Bajwa, Klatt, Li & Maguire, 1998) . No contaminating virus was detected.
Intraocular administration of recombinant 6irus
All animals were cared for in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, with federal, state and local regulations and in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC). The minimal number of animals was used to obtain statistically significant results. Studies were performed on a large number of mice (n = 60) in order to obtain statistically significant results. A smaller number of dogs (n=6) was used to determine whether the results in mice were specific to that species or to the type of surgical approach necessary in the small mouse eye. An additional advantage of the dog is that intraocular fluid can be tapped from the dog eye (but not in the small mouse eye) in order to evaluate intraocular antibody response.
Mice
Injections were performed through a transscleral transchoroidal approach as described. Subretinal and intravitreal administration of 1-2 ml of infection solution (containing totals of 5× 10 8 infectious units (iu) (or 3× 10 9 particles) of AAV-GFP or 5×10 8 pfu (or 5 × 10 9 particles) of Ad.CMVGFP) were performed. Contralateral eyes were used as control. Cohorts of ten adult mice (6-8 week old immunocompetent C57Bl/6 mice) were used in experiments evaluating each virus and also in side-by-side comparisons of the two viruses.
Sham injection, injections of buffer alone and injections of rAAV containing the human bcl-2 cDNA instead of GFP (AAV.bcl-2) were performed as controls. Experiments were repeated four times.
Dogs
Injections of rAAV-GFP were performed in two 2.25 month old dogs with phenotypically wildtype retinas. One eye of each dog received a subretinal injection and the contralateral eye received an intravitreal injection. Each eye received a total of 2.4 × 10 11 iu except for one eye which received 1.2 ×10 10 iu. The eye which received the lower dose was one which was injected subretinally. In summary, the total dose of one dog (dog c 1219) was 4.8×10 11 iu (half intravitreally, half subretinally) and that of the other dog (dog c 1400), 2.5× 10 11 iu (2.4 × 10 11 intravitreally and 1.2× 10 10 subretinally). Control intravitreal and subretinal injections of vehicle alone were performed in eyes of additional animals (n= 4 for each type of injection) of the same age. The details of the surgical procedures are as follows: dogs were pre-anesthetized with pre-acepromazine, 0.1-0.3 mg kg − 1 IM then atropine 0.04 mg kg − 1 IM. Induction (after aseptic preparation of the site of venipuncture) was with thiopental, 1cc/6 lbs IV of a 2% solution. This was followed by intubation and ventilation with 2.5% isofluorane. The pupils were dilated with mydriacyl (tropicamide) 1% and mydfin (phenylephrine hydrochloride) 2.5% and a fornix-based conjunctival peritomy was performed in one quadrant to expose the underlying sclera. The external sclera was lightly treated with cautery at the incision site. An anterior chamber paracentesis was performed with a 30 gauge needle to soften the eye prior to injection and to obtain fluid for baseline intraocular antibody measurements. A 30 gauge anterior chamber cannula (Storz) was inserted through a sclerotomy 2 mm posterior to the limbus at the 2:00 position and a 27 gauge needle was used to incise the sclera approximately 2 to 3 mm posterior to the corneoscleral limbus. A 30 gauge blunttipped anterior chamber infusion cannula was introduced through the scleral incision into the vitreous. While under direct visualization with an operating microscope and a plano convex fundus contact lens, purified rAAV-GFP was injected into the vitreous (0.25 ml containing 9.4×10 10 iu) or into the subretinal space (0.05 ml containing 1.9×10 10 iu) of the nontapetal retina. Retinal vessels remained well perfused during and following the procedure.
In 6i6o assessment of GFP expression
Animals were monitored for GFP expression by indirect ophthalmoscopy at weekly intervals following injection as described (Bennett et al., 1997) . Fundus photographs were taken with a Kowa camera (Keeler Instruments, Broomall, PA) equipped with a Wratten c47B gelatin excitation filter (Kodak, Rochester, NY).
Histological analyses
Mice
At necropsy, animals were perfused with 4% paraformaldehyde and eyes and brains were fixed in this same fix for 24 h at room temperature under vacuum. Tissue was cryoprotected through successive incubations (12 h each under vacuum) in 10, 20 and 30% sucrose (w/v) dissolved in saline.
Dogs
A 1 cm incision was made at the corneal limbus at the time of enucleation and eyes were fixed in 4% paraformaldehyde for 4 h on ice. Eyecups were dissected away from the anterior segment and the lens and vitreous were removed. Ocular tissue was fixed for an additional 24 h at room temperature under vacuum. The brain was immersed in 4% paraformaldehyde at 4°C at necropsy and was fixed intact under vacuum for 4 days. Dog eyes and brain were cryoprotected in a similar mode as the mouse tissue except that samples were immersed in each successive solution change for 24 h. Brains were bisected and each half was cut into four separate blocks.
Tissues were immersed in optimal temperature compound (O.C.T., Baxter) and frozen in dimethylpentane in a dry ice bath. Serial sections were cut at 10 -30 mm on a Reichert-Jung cryostat at − 23°C. GFP was detected in whole mount tissue using an inverted Nikon diaphot microscope equipped with FITC filters or in tissue sections using a Leica DMXRE microscope (equipped with the same filters). Adjacent sections were observed under bright field after staining with hematoxylin and eosin in order to evaluate presence of inflammatory cells.
Enzyme-linked immunoabsorbant assay (ELISA)
Samples were analyzed for antibodies to viral capsid proteins using ELISA. Enhanced protein binding ELISA plates were coated overnight at 4°C with antigen (purified AAV) and then washed, blocked and incubated with diluted (1:100, 1:400, 1:1600) serum or intraocular fluid. Saline was used as negative control for the mice. Serum from a human patient previously found to have high levels of anti-AAV antibodies (CF 493 c31, kindly provided by N. Chirmule) was used as a positive control. Samples were incubated with a 1/ 1000 dilution of a peroxidase-conjugated goat-a-mouse IgG (Jackson ImmunoResearch, 100 ml/well) and washed. The Peroxidase Substrate System (Kirgaard & Perry Laboratories) was used for the color reaction and the plates were read at an optical density of 405 nm. Measurements were repeated three times.
Western analysis
Humoral immune response to GFP was assessed by Western blot analysis using modifications of techniques described by Bennett, Pakola, Zeng and Maguire, 1996 . The modifications are as follows: each lane of a discontinuous SDS (0.04%)-polyacrylamide (10%) 1 mm analytical gel was loaded with 1 mg purified EGFP (Clontech). After transfer to nitrocellulose and division of nitrocellulose into vertical strips, each strip was exposed to the primary 'antibody' solution (5 ml of the appropriate serum sample diluted 1:250) in blocking buffer at 4°C for 12 h. After washing, strips were incubated with the secondary antibody, peroxidase-labeled anti-mouse or anti-dog antibody (Jackson Immunoresearch) diluted 1:1000 for 1 h at room temperature. Negative control 'primary antibodies' consisted of naive mouse and dog serum. Positive controls consisted of strips incubated with a GFP polyclonal antibody (diluted 1:250; Clontech, Palo Alto, CA).
After application of the secondary antibody, the blots were washed and peroxidase activity was measured after reaction with the ECL Western detection kit (Amersham, Arlington Heights, IL) according to the manufacturer's directions.
Results
In 6i6o assessment of GFP fluorescence
GFP was not detected ophthalmoscopically in AAV-GFP-injected eyes until 2-3 weeks after injection as described previously (Bennett et al., 1997) . At that time, fluorescence was weak. As described previously in mice, in both mice and dogs, regions with localized GFP fluorescence were observed in eyes that had received subretinal injections. Although there was variability from eye to eye, GFP expression in mice receiving subretinal injection was often intense enough at 6 weeks to detect by illuminating the animal with blue light (Fig. 1A) . Examination of these animals with illumination through a lens revealed widespread green fluorescence (Fig. 1B) . Levels remained stable through the 8 month timepoint (termination of the experiment). No fluorescence was detected in control retinas at any timepoint. Fluorescence was not detected ophthalmoscopically after intravitreal injection in mice.
Because of the reflective tapetum in the dog (but not the mouse), GFP fluorescence did not contrast as sharply with the background pigmentation in the dog as in the mouse. A representative photograph from a dog eye showing a patch of fluorescing retina 6 weeks after subretinal injection of AAV -GFP is shown in Fig. 1C . Fluorescence was much more subtle and diffuse in eyes receiving intravitreal injection ( Fig. 1D ; arrow indicates small patch of fluorescing cells). As with the mouse, ophthalmoscopically detectable GFP fluorescence peaked by 6 weeks after injection in dog eyes that received subretinal injection. Levels remained stable through 23 weeks after injection without diminution (longest timepoint). There was no evidence of GFP expression in eyes which were used as control or in anterior segment structures of AAV-GFP-injected eyes. There was no clinical evidence of inflammation or discomfort in mice or dogs at any point after injection of AAV -GFP. Corneas and media remained clear following injection, there was no excessive tearing, conjunctiva remained uninjected and animals maintained normal levels of activity and consumption of food and water.
E6aluation of ocular tissue by microscopy
Confirmation of cellular specificity and location of fluorescence was made histologically after tissue harvest. After subretinal injection of rAAV -GFP the predominant cell types expressing GFP were those of the outer retina (photoreceptors and RPE cells), as described previously (Bennett et al., 1997) . Large patches of fluorescing photoreceptors were observed in mice and dogs ( Fig. 2A, B; Fig. 4A ). Fluorescence in underlying RPE cells was often intense (not shown). GFP expression was not detected in photoreceptors or RPE cells outside of the region of subretinal injection. However, those regions possessed occasional GFP-expressing ganglion cells (Bennett et al., 1997) .
Intravitreal injection of rAAV-GFP resulted in transgene expression only in ganglion cells and cells of the inner retina in mice and dogs ( Fig. 2C, D; Fig. 4B ). No GFP was observed in cells of the outer retina. While GFP-expressing cells were found throughout the retinas after intravitreal injection, the portion of the retina exposed to the highest concentration of virus (that region closest to the needle) had the highest concentration of expressing cells. GFP-expressing ganglion cell axons could be traced through their exit of the retina within the optic nerve (Fig. 3A-C) . High levels of histologically detectable GFP persisted in eyes receiving subretinal or intravitreal AAV-GFP at least 7.5 months after injection (the latest timepoint). Fluorescence was not detected in control-injected retinas or optic nerves at any timepoint (Fig. 3D, E) . There was no evidence of inflammation or cellular infiltrate at any timepoint as assessed by counterstaining sections with hematoxylin and eosin or neutral red.
Whole mount examination of dissected mouse and dog brains from AAV-GFP-injected animals revealed the presence of fluorescing axons within the optic nerves and chiasm ( Fig. 3F, G; Fig. 4C ). Fluorescent decussating fibers could be identified in the optic chiasm as well as bead-like fluorescent out-pouchings emanating from the linear axons (see arrows, Fig. 3G ). No other surface structures of the brain possessed GFP-related fluorescence. Histological assessment of the brains revealed high levels of transgene expression in multiple tracts originating and branching from the optic nerves. Identification of transgene-expressing structures within the mouse brain was performed through identification of anatomical landmarks delineated in an atlas of the C57Bl/6 mouse brain (Franklin & Paxinos, 1997) . As shown in Fig. 5A -D, fluorescent axons were also observed in radiations as well as within the superior colliculi ( Fig. 5C-F ) and the laterogeniculate nuclei ( Fig. 5H-K) . Expression was often bilateral (even in mice in which AAV was injected unilaterally) due to decussations of the optic nerves at the optic chiasm. GFP was also detected in the suprachiasmatic nuclei, the paraventricular nuclei and the supraoptic nuclei. GFP was also observed in the dog brain, in the same optic nerve tracts as observed in mice (shown is the suprachiasmatic nucleus, Fig. 4D ). GFP expression was not detected in secondary neurons or in other portions of the brains of mice or dogs. No GFP fluorescence was detected in control retinas or optic nerves. Similar to the retinas, there was no clinical or histological evidence of inflammatory response in brains of animals injected intraocularly with rAAV. In order to determine whether GFP expression in the CNS related specifically to the rAAV vector, retinal and CNS-specific transgene expression patterns were analyzed in a group of ten mice injected with a recombinant adenovirus carrying the identical transgene cassette as rAAV-GFP. As expected given previous descriptions of retinal cell types targeted by recombinant adenovirus (Bennett, Wilson, Sun, Forbes & Maguire, 1994; Li, Adamian, Roof, Berson & Dryja, 1994) , high levels of GFP were detected in RPE cells 
Immune response to adeno-associated 6irus capsid proteins/green fluorescent protein
Previous studies on mice have demonstrated that intraocular delivery of adenovirus at the doses used does not result in significant systemic humoral response 10 iu rAAV -GFP. Arrow depicts a GFP-expressing region; (B) GFP expression is apparent in a representative ganglion cell of an eye that had received an intravitreal injection of 9.4 × 10 10 iu rAAV -GFP 3 weeks earlier; GFP expression can be traced through the optic nerve to the optic chiasm (C), where GFP-expressing axons from the contralateral injected eye are also observed (arrows indicate directions of optic nerves toward the chiasm). (D) GFP expression is observed in the suprachiasmatic nuclei in the brain of this dog. Bennett et al., 1996) . In order to assess the immunological consequences of intraocular injection of rAAV, we performed studies on serum samples of mice and on serum and anterior chamber fluids of dogs injected subretinally or intravitreally with rAAV. Subretinal and intravitreal injection of AAV -GFP or AAV-bcl-2 resulted in a small but statistically significant increase in Ig(G2b + G3) in serum over control (P =0.001) (Fig.  6A) . IgG2a antibodies were not detected (data not shown). Therefore, the immune response directed against AAV capsid proteins is a Th-2 (or Th-1 independent) response. The serum results in dogs paralleled those of the mice (Fig. 6B) . In addition, a small but reproducible antibody response (again Th-2) was detected through analyses of intraocular fluid samples.
Finally, humoral response to GFP itself was assessed by Western analysis in serum and intraocular fluid samples from dogs and serum samples from mice. Antibodies to GFP were not detected in mice by this method but were present in high levels in serum only in the dog ( c 1219) which received the higher dose of virus (lane 4 of Fig. 7 and data not shown).
Discussion
This study provides the first description of the ability to use rAAV to deliver a transgene product to the brain via ocular (ganglion cell) administration. Intraocular delivery of recombinant adenovirus, which does not transduce ganglion cells efficiently, does not result in delivery of the transgene product to the CNS. Ganglion cells, however, are transduced efficiently after intraocular (intravitreal) delivery of rAAV. After intraocular injection of rAAV-GFP, GFP is detected in CNS tissues known to be enervated by retinal ganglion cells (Glaser & Sadun, 1990 ). This effect is not species-specific as similar results were obtained in the dog and in the mouse. Neither is the result dependent on surgical approach as the same effect was observed after transscleral/transchoroidal delivery as after delivery through a transvitreal approach.
The anatomical pathways connecting the retinal ganglion cells to the CNS have been well-documented through studies involving orthograde and retrograde transport of a variety of compounds, including labeled amino acids and proteins, histologically detectable enzymes (such as horseradish peroxidase) and fluorescent compounds. The molecules enter the retinal ganglion cells through internalization or can be delivered through microinjection (of individual cells). Retinal ganglion cell labeling mediated by rAAV, described here, is efficient, has minimal toxicity and selectively delivers the transgene to retinal ganglion cells (after intravitreal injection). Delivery of a protein (transgene product) through transduction with rAAV also presents two other advantages over traditional methods of introducing proteins into retinal ganglion cells. (1) Delivery of DNA encoding the transgene presents the possibility that the foreign protein can be produced continuously (as long as the transgene is transcribed). (2) Production of the protein product by the retinal ganglion cells themselves (and elimination of the internalization/transport steps) is likely to minimize the significant degradation that is observed after internalization of protein (Johnson, Andres & Bradshaw, 1978; Ferguson, Schweitzer & Johnson, 1990 In the study presented here, we have demonstrated that the GFP protein is stable in the transduced cells and delineates their anatomical pathways for at least 7.5 months after injection. There is no detectable humoral response to the transgenic protein. The antibody response to the rAAV capsid protein is Th-1-independent. This indicates that the cellular immune response to the vector is minimal, a fact supported by the lack of histological evidence of inflammation after injection of rAAV. These results suggest that rAAV may be a powerful tool with which to label or experimentally manipulate retinal ganglion cell targets in the brain. The results from the present study relate specifically to an intracellular cytoplasmic protein (GFP). What remains to be seen is whether AAV-mediated transgene delivery can be used to deliver intact membrane-bound or secreted proteins to the CNS. The ability of intraocularly delivered AAV to deliver secreted proteins to the brain is particularly attractive as the proteins would be biologically active beyond the distances traversed by the axons themselves. This possibility is currently under investigation in our laboratory.
Several exciting prospects will emerge should intraocular delivery of rAAV be capable of delivering biologi- cally active proteins to the brain. This virus could be used to deliver experimental compounds to specific portions of the optic nerve/brain in order to generate animal models for specific diseases. In addition, such results would also have important implications with respect to therapeutic applications of rAAV. It may be possible to harness rAAV as a vector with which to deliver genes therapeutic for such diseases as optic neuropathies, brain tumors and metabolic disorders.
The current findings also have important implications with respect to retinal gene therapy. Rescue of photoreceptors degenerating due to inherited retinal degeneration will likely require subretinal injection as this results in efficient transduction of these cells. The results indicate that even though subretinal injection primarily exposes cells of the outer retina, a sufficient amount of virus escapes into the vitreous cavity so that inner retinal ganglion cells are also transduced. Transgenes aimed at delivering therapeutic molecules to the retina may result in toxicity to the central nervous system. Incorporation of photoreceptor or RPE-specific promoters could be used to limit transgene expression to cells of the outer retina in retinal gene therapy. These promoters should be sufficient, if the transgene/virus/transgene product is not transmitted trans-synaptically. We have found no evidence of trans-synaptic transmission of virus, as there is no transgene expression beyond the first synapse of the transduced cells.
Finally, results from this study confirm earlier findings relating to the stability and efficiency of rAAVmediated transduction of neuronal cells-particularly of photoreceptors. Interestingly, while minimal evidence of inflammatory response is observed, ocular administration of rAAV results in a small but significant increase in rAAV-specific antibody response systemically. A small rAAV-specific antibody response is also observed within the intraocular fluid (of the dog). Interestingly, one of the dogs also possessed a strong systemic (but not intraocular) antibody response to the GFP protein. Experiments, in progress, will determine whether presence of anti-AAV antibody is sufficient to neutralize subsequent administration of vector. Additional studies will reveal whether antibody response to the transgene product itself will limit utility of intraocular gene delivery. These issues will be important for studies designed to treat slowly progressive inherited retinal degenerations like retinitis pigmentosa.
